Application of fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma
By using the fatty acid oxidation inhibitor Etomoxir to inhibit GDF15 secreted by M2 macrophages, the problem of esophageal squamous cell carcinoma resistance to cisplatin was solved, the chemotherapy sensitivity of esophageal squamous cell carcinoma was improved, and the effect of improving the efficacy of chemotherapy was achieved.
Patent Information
- Application Number
- CN202410933000.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-22
AI Technical Summary
Patients with esophageal squamous cell carcinoma have strong resistance to cisplatin chemotherapy, resulting in poor treatment effect. The existing mechanism is not completely clear, especially the regulatory effect of M2 tumor-related macrophages on fatty acid β oxidation in esophageal cancer. .
Using the fatty acid oxidation inhibitor Etomoxir, GDF15 secreted by M2 macrophages, thereby reducing the resistance of esophageal squamous cell carcinoma cells to cisplatin, and treatment was carried out in combination with cisplatin.
It effectively weakens the chemotherapy resistance process of tumor-associated macrophages mediated by esophageal cancer, improves the sensitivity of esophageal squamous cell carcinoma to cisplatin, and improves the efficacy of chemotherapy.
Smart Images

Figure CN118986956A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to application of a fatty acid oxidation inhibitor in improving cisplatin resistance in esophageal squamous cell carcinoma. Background Art
[0002] Esophageal cancer is a common malignant digestive tract tumor, which is mainly divided into two subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Esophageal squamous cell carcinoma is the most common in my country. Although surgery is considered to be an effective method for treating early esophageal squamous cell carcinoma, the early symptoms of the disease are not obvious, and once diagnosed, the disease is often in the middle and late stages, and the opportunity for surgery is often lost. Therefore, chemotherapy, radiotherapy, and immunotherapy are still the main treatment options for patients with middle and late esophageal squamous cell carcinoma. Cis-diamine dichloroplatinum (CDDP) is the most important chemotherapy drug for the treatment of esophageal cancer. However, although cisplatin has a certain improvement effect on the progression of esophageal cancer, the occurrence of drug resistance greatly affects the clinical efficacy of cisplatin, resulting in poor prognosis for patients. At present, the mechanism of chemotherapy resistance in esophageal cancer is not fully clear. Therefore, understanding the mechanism of chemotherapy resistance in esophageal cancer is of great significance to improving the chemotherapy efficacy of patients with esophageal cancer.
[0003] Recent studies have found that the tumor microenvironment plays an important role in the occurrence of chemotherapy resistance in esophageal cancer. Among them, macrophages account for a considerable proportion in the tumor microenvironment. They can be divided into M1 and M2 types according to their functions. M2 tumor-associated macrophages are believed to promote tumor chemotherapy resistance, but the specific mechanism has not yet been fully clarified. Metabolic reprogramming is one of the important hallmarks of malignant tumor cells. Studies have found that abnormal lipid metabolism is an important accomplice in the development of tumor cells. Among them, fatty acid metabolism has been reported to be involved in the stemness, metastasis and chemotherapy resistance of tumors. In malignant tumors such as colorectal cancer and gastric cancer, it was found that M2 tumor-associated macrophages can mediate the activation of the fatty acid β-oxidation pathway, leading to enhanced stemness and chemotherapy resistance of tumor cells. However, the regulatory role of M2 tumor-associated macrophages on fatty acid β-oxidation in esophageal cancer is still unclear, and whether fatty acid β-oxidation inhibitors can be used in the chemotherapy process of esophageal cancer has not been reported. Summary of the invention
[0004] To this end, the present invention provides the use of a fatty acid oxidation inhibitor in improving cisplatin resistance in esophageal squamous cell carcinoma cells, so as to solve the serious problem of cisplatin resistance in existing treatments for esophageal squamous cell carcinoma cells.
[0005] In order to achieve the above object, the present invention provides the following technical solutions:
[0006] According to the first aspect of the present invention, a fatty acid oxidation inhibitor is provided for use in the preparation of a product for improving cisplatin resistance in esophageal squamous cell carcinoma.
[0007] Furthermore, the fatty acid oxidation inhibitor is etomoxir.
[0008] Etomoxir (ETO) is an FDA-approved CPT1 targeted inhibitor that lowers blood sugar by increasing the sensitivity of adipocytes to insulin and inhibiting gluconeogenesis in hepatocytes. It has been used in the clinical treatment of type 2 diabetes. Recent studies have shown that etomoxir plays an important role in the treatment of tumors. In triple-negative breast cancer and prostate cancer, etomoxir can inhibit the proliferation of nude mouse transplanted tumors. In acute myeloid leukemia, etomoxir can induce apoptosis of leukemia cells and increase the sensitivity of quiescent leukemia progenitor cells to the chemotherapy drug cytosine arabinoside. Etomoxir can inhibit the stemness of stem cells in liver cancer and increase the sensitivity of liver cancer stem cells to the targeted drug sorafenib.
[0009] Furthermore, the esophageal squamous cell carcinoma is an esophageal squamous cell carcinoma cell mediated by M2 macrophages.
[0010] Furthermore, the esophageal squamous cell carcinoma cells are EC109 and / or KYSE150.
[0011] Furthermore, the fatty acid oxidation inhibitor improves the cisplatin resistance of esophageal squamous cell carcinoma cells by inhibiting fatty acid β-oxidation, thereby weakening the cisplatin resistance of esophageal squamous cell carcinoma cells induced by M2 macrophage-derived GDF15.
[0012] Furthermore, the inhibition of fatty acid β-oxidation is through the inhibition of GDF15 secreted by M2 tumor-associated macrophages.
[0013] According to a second aspect of the present invention, a drug for improving cisplatin resistance of esophageal squamous cell carcinoma cells is provided, wherein the drug comprises etomoxir, a fatty acid oxidation inhibitor.
[0014] According to a third aspect of the present invention, a drug for treating esophageal squamous cell carcinoma is provided, wherein the drug comprises a fatty acid oxidation inhibitor and cisplatin.
[0015] Furthermore, the drug also includes commonly used pharmaceutical carriers and pharmaceutical excipients.
[0016] The drug for improving the cisplatin resistance of esophageal squamous cell carcinoma cells is made into pharmaceutical dosage forms, and the dosage forms include sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, instant powders, pills, pills, suspensions, powders, wine preparations, preparations, drops, injections, powder injections, creams, sustained-release agents, targeted agents, etc., and are used as drugs for improving the cisplatin resistance of esophageal squamous cell carcinoma cells.
[0017] The administration method of the drug for improving cisplatin resistance of esophageal squamous cell carcinoma cells includes oral administration, injection, implantation, external application, spraying, inhalation or a combination thereof.
[0018] The present invention has the following advantages:
[0019] The present invention discloses for the first time that the fatty acid β-oxidation inhibitor Etomoxir has a good effect on reducing the cisplatin resistance of esophageal squamous cell carcinoma cells induced by M2 macrophage-derived GDF15.
[0020] The present invention effectively weakens the chemotherapy resistance process of esophageal cancer mediated by tumor-associated macrophages by applying the fatty acid β-oxidation inhibitor Etomoxir in combination with cisplatin to the treatment process of esophageal cancer.
[0021] The present invention aims at the problem that M2 tumor-associated macrophages lead to reduced chemotherapy sensitivity in patients with esophageal cancer, and uses the fatty acid oxidation inhibitor Etomoxir in combination with cisplatin treatment to improve the cisplatin resistance of esophageal cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0023] The structures, proportions, sizes, etc. illustrated in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with the technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantial technical significance. Any structural modification, change in proportion or adjustment of size shall still fall within the scope of the technical contents disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.
[0024] Figure 1 A STAT3 overexpression plasmid map provided by the present invention;
[0025] Figure 2 A GPL-4 firefly luciferase plasmid map provided by the present invention;
[0026] Figure 3 A GPL-4 Renilla luciferase plasmid map provided by the present invention;
[0027] Figure 4A diagram of M2 tumor-associated macrophages promoting fatty acid β-oxidation in esophageal squamous cell carcinoma cells provided in an embodiment of the present invention; wherein, A-Oil Red O staining diagram; B-qRT-PCR detection of the expression of genes related to fatty acid metabolism in esophageal squamous cell carcinoma cells EC09 and KYSE150 promoted by M2-TAMs conditioned medium under cisplatin treatment; C-a diagram of changes in the fatty acid β-oxidation rate of esophageal squamous cell carcinoma cells EC09 and KYSE150 after esophageal squamous cell carcinoma cells were treated with conditioned medium of M2-TAMs for 48 hours; D-a diagram of changes in the activity of CPT1, the rate-limiting enzyme for fatty acid β-oxidation in tumor cells EC09 and KYSE150, after conditioned medium of M2-TAMs acted on esophageal squamous cell carcinoma cells for 48 hours; E-a diagram of changes in ATP generation in tumor cells EC09 and KYSE150, after conditioned medium of M2-TAMs acted on esophageal squamous cell carcinoma cells for 48 hours;
[0028] Figure 5 A graph showing the inhibition of cisplatin resistance of M2 tumor-associated macrophages to esophageal squamous cell carcinoma cells by the fatty acid β-oxidation inhibitor Etomoxir provided in an embodiment of the present invention; wherein A-changes in cisplatin IC50 values of tumor cells after esophageal squamous cell carcinoma cells are treated with M2-CM or Etomoxir (100 ng / mL) alone or in combination; B-plate clone formation assay to detect the effects of M2-CM or Etomoxir (100 ng / mL) alone or in combination on the proliferation activity of esophageal squamous cell carcinoma cells in the absence or presence of 4 μg / mL cisplatin; C-flow apoptosis assay to detect changes in apoptosis ability of esophageal squamous cell carcinoma cells in a culture medium containing 4 μg / mL cisplatin by M2-CM or Etomoxir (100 ng / mL) alone or in combination;
[0029] Figure 6GDF15 secreted by M2 tumor-associated macrophages provided in the embodiment of the present invention is a key cytokine that promotes fatty acid β-oxidation in esophageal squamous cell carcinoma cells; wherein A-multifactor antibody chip detects the expression of cytokines in the supernatant of esophageal squamous cell carcinoma cell line EC109, M2-TAMs cultured alone, and EC109 and M2-TAMs co-culture system; B-TCGA database ESCA GDF15 expression level in cancer; C-GDF15 expression level is associated with poor overall survival of ESCA patients; D-TIMER database analysis of ESCA The expression level of the GDF15 gene in patients was correlated with the degree of M2-TAMs infiltration; the E-GEPIA2 database analyzed the correlation between the expression level of GDF15 in ESCA patients and the macrophage markers CD68 and CD204; the F-GEPIA2021 database analyzed the expression of GDF15 in M2 macrophages in ESCA patients; G-ELISA detected the expression level of GDF15 in the supernatant of esophageal squamous cell carcinoma cells EC109, KYSE150, THP-1, M0-TAMs, and M2-TAMs cultured alone; H-Changes in GDF15 secretion in esophageal squamous cell carcinoma cells EC109, KYSE150 before and after co-culture with M2-TAMs; I-Changes in GDF15 secretion in M2-TAMs before and after co-culture with esophageal squamous cell carcinoma cells EC109, KYSE150; J-Correlation between GDF15 gene expression and FAO regulatory genes PGC1α, CPT1A, and CPT2 in esophageal cancer in the TCGA database; K-GS of esophageal cancer patients grouped by high and low expression of GDF15 EA enrichment analysis diagram; L-Expression diagram of FAO-related genes after exogenous GDF15 acts on two esophageal squamous cell carcinoma cells; M-Changes in fatty acid β-oxidation rate of esophageal squamous cell carcinoma cells under the action of M2-CM and M2-CM+anti-GDF15 antibody; N-Changes in fatty acid β-oxidation rate of esophageal squamous cell carcinoma cells after 48 hours of treatment with exogenous recombinant GDF15 protein; O-CPT1 enzyme activity of esophageal squamous cell carcinoma cells after 48 hours of treatment with exogenous recombinant GDF15 protein; P-ATP generation diagram of esophageal squamous cell carcinoma cells after 48 hours of treatment with exogenous recombinant GDF15 protein;
[0030] Figure 7A diagram showing that M2 tumor-associated macrophage-derived GDF15 promotes fatty acid β-oxidation in esophageal squamous cell carcinoma cells by activating the STAT3 pathway, provided in an embodiment of the present invention; wherein, A-KEGG analysis diagram of transcriptome sequencing data of esophageal squamous cell carcinoma cell EC109 after co-culture; B-Western blot detection of changes in the phosphorylation level of STAT3 signaling pathway proteins in esophageal squamous cell carcinoma cells under the action of M2-TAMs conditioned medium and GDF15 neutralizing antibody; C-activation of the STAT3 signaling pathway after the action of exogenous GDF15 protein with increasing concentration gradient on two esophageal squamous cell carcinoma cells; D-Changes in the FAO rate of ESCC cells under the action of M2-TAMs conditioned medium after ESCC cells were pretreated with the STAT3 pathway inhibitor stattic for 24 hours; E-Changes in the ATP production of ESCC cells under the action of M2-TAMs conditioned medium after ESCC cells were pretreated with the STAT3 pathway inhibitor stattic for 24 hours; F-Changes in the CPT1 enzyme activity of ESCC cells under the action of M2-TAMs conditioned medium after ESCC cells were pretreated with the STAT3 pathway inhibitor stattic for 24 hours;
[0031] Figure 8 STAT3 provided in the embodiment of the present invention promotes fatty acid β-oxidation in esophageal squamous cell carcinoma by positively regulating the transcriptional activity of CPT1B; wherein A-TCGA database ESCA transcriptome data analysis found the correlation between STAT3 and FAO rate-limiting enzyme CPT1B; B-After siRNA knockdown of STAT3, the mRNA expression levels of CPT1A, CPT1B, and CPT1C in esophageal squamous cell carcinoma cells changed; C-After plasmid overexpression of STAT3, the mRNA expression levels of CPT1A, CPT1B, and CPT1C in esophageal squamous cell carcinoma cells changed; D-; E-siRNA knockdown of STA After T3, the protein expression level changes of CPT1A, CPT1B, and CPT1C in esophageal squamous cell carcinoma cells; F- After plasmid overexpression of STAT3, the protein expression level changes of CPT1A, CPT1B, and CPT1C in esophageal squamous cell carcinoma cells; G- After knocking down STAT3 in wild-type and mutant esophageal squamous cell carcinoma cells of CPT1B promoter using siRNA, the change of fluorescence intensity values of wild-type and mutant cells; H- After plasmid overexpression of STAT3 in wild-type and mutant esophageal squamous cell carcinoma cells of CPT1B promoter using plasmid, the change of fluorescence intensity values of wild-type and mutant cells;
[0032] Fig. 9The inhibition of fatty acid β-oxidation provided in the embodiments of the present invention can weaken the cisplatin resistance of esophageal squamous cell carcinoma cells induced by M2 macrophage-derived GDF15; wherein, the A-CCK8 experiment detects the change in the cisplatin IC50 value after the exogenous GDF15 protein combined with Etomoxir acts on esophageal squamous cell carcinoma cells; the B-clone formation experiment detects the proliferation of esophageal squamous cell carcinoma cells in 4 μg / mL cisplatin culture medium after the exogenous GDF15 protein combined with Etomoxir acts on the esophageal squamous cell carcinoma cells. DETAILED DESCRIPTION
[0033] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] The human esophageal squamous cell carcinoma cell line EC109 was purchased from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and the human esophageal squamous cell carcinoma cell line KYSE150 and the human leukemia monocytic cell line THP-1 were purchased from the Shanghai Cell Bank, Chinese Academy of Sciences.
[0035] Western blot related antibody information is shown in Table 1.
[0036] Table 1
[0037]
[0038] The information about immunohistochemical antibodies is shown in Table 2.
[0039] Table 2
[0040]
[0041] STAT3 overexpression plasmid was designed and synthesized by Genema Gene Co., Ltd. Figure 1 , dual luciferase reporter gene vector plasmid (such as Figure 2 ) and mutant plasmids (such as Figure 3 ) was designed and synthesized by Jima Genetics.
[0042] See Table 3 for STAT3 small interfering RNA sequence information:
[0043] Table 3
[0044]
[0045] The experimental reagents are shown in Table 4:
[0046] Table 4
[0047]
[0048]
[0049] The present invention adopts Spearman correlation analysis to analyze the correlation of each index, Kaplan-Meier method to analyze survival analysis, Student's t test to compare two groups of independent samples, variance analysis or rank sum test to analyze the difference between groups of three or more groups. All analyses were performed using SPSS26.0 statistical software, and images were drawn on Graphpadprism 8.0 software, ns means P>0.05, * means P<0.05, ** means P<0.01, *** means P<0.001.
[0050] Example
[0051] The main solutions are shown in Table 5.
[0052] Table 5
[0053]
[0054]
[0055] 1. Obtaining M2-TAMs conditioned medium: Select THP-1 cells in the logarithmic growth phase for induction. Add 4 μL of phorbol ester to each 4 ml culture flask under light-proof conditions, gently mix the cell suspension, and culture in a cell culture incubator for 36 hours. Take out the cells and observe the cell morphology under a microscope. When the morphology of M0 macrophages appears, discard the cell culture medium, wash the residual phorbol ester with pre-cooled 1× PBS, and add 4 μL of IL-4 and IL-13 to each 4 ml cell culture flask after absorbing all the 1× PBS. Continue to culture for 48 hours. The cells were induced into M2-TAMs; the original M2-TAMs culture medium was discarded, the cells were washed twice with 1×PBS, and new RPMI1640 culture medium without serum and double antibody was added. The cells were cultured for 48 hours and then the culture medium was collected; the collected conditioned medium was centrifuged at 3000×g for 10 minutes, the cell supernatant was retained, and the residual cell pellet was discarded. The collected conditioned medium was frozen in a -80°C refrigerator when it could not be used immediately; when co-cultured, the thawed M2-TAMs conditioned medium was mixed with RPMI1640 at a ratio of 1:1 and then used.
[0056] 2. Oil Red O Staining
[0057] Esophageal squamous cell carcinoma cells EC109 and KYSE150 were taken and placed in 6-well plates and treated in groups. The grouping is as follows: normal culture medium + 4 mg / L CDDP treatment, M2-TAMs conditioned culture medium + 4 mg / L CDDP treatment. After 48 hours of treatment, the culture medium was aspirated along the wall and washed twice with pre-cooled 1×PBS; 4% paraformaldehyde was added to fix the cells for 10 minutes, and the formaldehyde was discarded and washed three times with 1×PBS; 500μL staining washing solution was added to cover the cells for 20 seconds; the staining washing solution was aspirated with a pipette, 1mL Oil Red O staining solution was added, and staining was performed for 30 minutes; the Oil Red O staining solution was aspirated and 1mL staining washing solution was added to wash for 30 seconds; the washing solution was removed and washed with PBS for 20 seconds; 1mL 1×PBS was added to cover the cells, and then the cells were observed under an inverted microscope and photographed. For quantitative analysis, 1mL isopropanol was used to dissolve the Oil Red stained cells, and the absorbance value of the dissolved solution at 520nm was detected on an enzyme reader. The results are as follows. Figure 4 As shown in A, Figure 4 As shown in A, Oil Red O staining detected that the conditioned medium of M2-TAMs significantly increased the lipid deposition of EC109 and KYSE150 cells under the action of cisplatin.
[0058] 3.CCK8 Experiment
[0059] Digest the adherent EC109 and KYSE150 cells, add 1 mL of complete medium to resuspend the cell pellet after centrifugation and count; pre-design the required number of wells, plate 3,000 cells per well in a 96-well plate, ensure that the volume of each well is 100 μL, set 5 replicates for each test group, place the 96-well plate with cells in a cell culture incubator and culture for 12 hours, and then group them in the following ways: normal culture medium treatment group, M2-TAMs conditioned medium treatment group, Etomoxir treatment group, M2-TAMs conditioned medium + Etomoxir treatment group, GDF15 recombinant Protein treatment group, GDF15 recombinant protein + Etomoxir treatment group; and the medium was changed according to the added stimulation conditions, and after the medium change was completed, the cells were placed in a cell culture incubator for 48 hours; after the culture time was up, CCK8 reagent was added to each well at a volume of 10 μL under light-proof conditions, and after the addition was completed, the cells were cultured in a 37°C cell culture incubator for 2 hours for color development; after the color development was completed, a full-wavelength microplate reader was used to shake for 10 seconds, and then the absorbance value of each well at a wavelength of 450 nm was detected, and the detection was repeated 3 times; the cell proliferation ability was calculated according to the instructions; and the half-inhibitory concentration was calculated using graphpad software.
[0060] The experimental results are as follows Figure 5 A and Fig. 9 As shown in A, Figure 5A shows that M2-TAMs conditioned medium can promote the proliferation of EC109 and KYSE150 cells, and Etomoxir reverses the promoting effect of M2-TAMs conditioned medium on the proliferation of EC109 and KYSE150 cells; Fig. 9 A shows that GDF15 recombinant protein can promote the proliferation of EC109 and KYSE150 cells, and Etomoxir reverses the promoting effect of GDF15 recombinant protein on the proliferation of EC109 and KYSE150 cells.
[0061] 4. Plate colony formation experiment
[0062] After treating and digesting EC109 and KYSE150 cells, they were counted and 800 cells per well were transferred to a 6-well plate. According to the treatment conditions, they were divided into control group, M2-CM group, Etomoxir group, M2-CM+Etomoxir group; CDDP group, M2-CM+CDDP group, Etomoxir+CDDP group, M2-CM+Etomoxir+CDDP group; GDF15 group, GDF15+Etomoxir group, GDF15+Etomoxir+CDDP group. Two replicate control wells were laid in each group, and the liquid in each well was filled to 2 mL and placed in an incubator; fresh culture medium was replaced every 3 days, and the cell morphology was observed to be normal; when the white dot-like cell clusters could be observed from the bottom of the 6-well plate with the naked eye for about 14 days, the culture could be stopped for the subsequent steps. PBS rinsing was repeated 3 times, and 4% paraformaldehyde was used for each well with 2 mL. After treatment for 30 minutes, the 4% paraformaldehyde was poured out and placed in a clean place to dry. After adding 0.1% crystal violet for 25 minutes, the crystal violet stain was discarded and the residual stain was washed off with 1× PBS. A camera was used to take pictures and statistical analysis was performed after calculation using the PS counting tool.
[0063] The results are as follows Figure 5 As shown in Figure B, it can be seen that Etomoxir can inhibit the proliferation of esophageal squamous cell carcinoma cells EC109 and KYSE150 by M2-CM, and this inhibitory effect is more obvious under the action of CDDP, as shown in Fig. 9 As shown in Figure B, it can be seen that GDF15 can promote the proliferation of esophageal squamous cell carcinoma cells EC109 and KYSE150, while Etomoxir can inhibit the proliferation-promoting effect of GDF15. The inhibitory effect of Etomoxir is more significant under the action of cisplatin.
[0064] 5. Flow cytometry apoptosis assay
[0065] 1) Adjustment of flow cytometer parameters
[0066] Collect 4×10 untreated EC109 and KYSE150 cells6 Wash twice with pre-cooled 1×PBS by centrifugation, and discard the supernatant; resuspend with 500μL apoptosis activator, and incubate in a 4℃ refrigerator for 30 minutes to cause cell apoptosis; wash with pre-cooled 1×PBS by centrifugation, and discard the supernatant; resuspend with 500μL pre-cooled 1× binding buffer, and add 500μL of the same amount of blank control cell suspension to mix with it. After adding 500μL of pre-cooled 1× binding buffer, divide 1.5mL of cell suspension into three tubes, one of which is a blank control tube and two are single-stain compensation tubes; 5μL AnnexinV-PE and 10μL 7-AAD are added to the single-stain tubes in order, incubate at room temperature in the dark for 3 to 5 minutes, and then use the flow cytometer for detection, use the blank tube to adjust the voltage, and use two single-stain tubes to adjust the compensation of each channel.
[0067] 2) Sample testing
[0068] Induce cell apoptosis according to the stimulation scheme of CDDP group, M2-CM+CDDP group, Etomoxir+CDDP group, and M2-CM+Etomoxir+CDDP group. Collect the induced apoptotic cells (including dead cells in the culture medium). Centrifuge at 800rpm for 5 minutes, collect the cell supernatant, dilute 5× binding buffer with double distilled water to 1× working solution, and resuspend the cells with 500μL 1× working solution. Add 5μL AnnexinV-PE and 10ul7-ADD to each tube of cells in a light-proof environment. Gently mix with a 10μL pipette and incubate at room temperature in the dark for 5 minutes; use a 1mL pipette to transfer each tube of cells to the flow cytometer tube; and detect the apoptosis rate on the flow cytometer.
[0069] The results are as follows Figure 5 As shown in Figure C, it can be seen that M2-CM can inhibit the apoptosis of esophageal squamous cell carcinoma cells EC109 and KYESE150 under the action of cisplatin, while the addition of Etomoxir reversed this trend.
[0070] 6. Western blot experiment
[0071] The esophageal squamous cell carcinoma cells were treated as follows: M2-CM treatment group, M2-CM+GDF15 neutralizing antibody treatment group, and GDF15 recombinant protein gradient treatment group. After protein extraction, SDS-PAGE electrophoresis was performed, and blocking and incubation were performed according to the relevant antibody information of western blot. The instructions of the ultrasensitive ECL luminescence kit were used to detect β-actin, STAT3, and p-STAT3. The results are shown in the figure. Figure 7 B. Figure 7C. As shown in Figure 7B, M2-CM can promote the phosphorylation of STAT3 pathway in esophageal squamous cell carcinoma cells EC109 and KYSE150 cells, while the addition of GDF15 neutralizing antibody inhibits the phosphorylation of STAT3 pathway in esophageal squamous cell carcinoma cells mediated by M2-CM. As shown in Figure 7C, the phosphorylation degree of STAT3 pathway in esophageal squamous cell carcinoma cells EC109 and KYSE150 cells increases with the increase of GDF15 recombinant protein concentration.
[0072] The esophageal squamous cell carcinoma cells were treated as follows: control group, STAT3 knockdown group, and STAT3 overexpression group. The proteins were extracted for SDS-PAGE electrophoresis, and the expressions of β-actin, STAT3, and CPT1B were detected after incubation with the corresponding antibodies. Figure 8 D shows that the expression level of CPT1B decreased after knockdown of STAT3 in esophageal squamous cell carcinoma cells. Figure 8 E shows that the expression level of CPT1B is increased after ESCC cells overexpress STAT3.
[0073] 7. Multifactor antibody chip detection
[0074] Collect the supernatant of EC109, M2-TAMs cultured alone and EC109 and M2-TAMs co-cultured. Each sample requires at least 500 μg. Use 2 ml of blocking solution to block each membrane, shake and block for 1 hour at room temperature, use the corresponding ArrayBuffer to dilute the sample, add 1.5 ml of the diluted sample to each array, incubate in a refrigerator at 4°C overnight, wash the membrane three times with Washbuffer, add the diluted primary antibody, and incubate at room temperature for 1 hour; wash the membrane three times with Washbuffer, add streptavidin HRP, and incubate at room temperature for 1 hour; wash the membrane three times with Washbuffer, add 1 ml of luminescent colorimetric solution, and immediately present it on the chemiluminescent imaging instrument. The data analysis results are shown in the following figure. Figure 6 As shown in A, it can be seen from the figure that the content of GDF15 in the supernatant of M2-TAMs culture condition alone is the highest, the content of GDF15 in the supernatant of EC109+M2-TAMs co-culture condition is less than that of M2-TAMs culture condition alone, and the expression level of GDF15 in the supernatant of EC109 culture condition alone is the lowest.
[0075] 8. Bioinformatics Analysis
[0076] 1) Gene expression analysis: We analyzed the difference in RNA expression of GDF15 between esophageal cancer (182 cases) and normal esophageal tissue (286 cases) in the TCGA database based on the online website http: / / gepia2.cancer-pku.cn / #index. The analysis was set to default parameters. The analysis results are shown in Figure 2. Figure 6 As shown in B, the expression of GDF15 in esophageal cancer is significantly higher than that in normal esophageal tissue. Based on the online website http: / / gepia2021.cancer-pku.cn / , we analyzed the expression of GDF15 in different subtypes of macrophages in the esophageal cancer microenvironment. The analysis results are shown in Figure 6 As shown in F, the expression levels of GDF15 in M2 macrophages and M0 macrophages were significantly higher than those in M1 macrophages and monocytes;
[0077] 2) Correlation analysis: Based on the online website http: / / gepia2.cancer-pku.cn / #index, we used the spearman analysis method to analyze the correlation between GDF15 and the expression of macrophage marker gene CD68, M2 macrophage marker gene CD204, fatty acid β-oxidation related genes CPT1A, CPT2, PGC1α, and the expression correlation between STAT3 and CPT1B in esophageal cancer. The results are as follows Figure 6 As shown in E, the correlation coefficients between GDF15 and CD68 and CD204 were 0.13 and 0.24, respectively; Figure 6 As shown in J, the correlation coefficient between GDF15 and CPT1A is 0.3, the correlation coefficient between GDF15 and CPT2 is 0.22, and the correlation coefficient between GDF15 and PGC1α is 0.37; Figure 8 As shown in A, the correlation coefficient between STAT3 and CPT1B was 0.22;
[0078] 3) Immune infiltration analysis: We analyzed the correlation between GDF15 expression and macrophage infiltration in esophageal cancer samples in the TIMER database based on the online website https: / / cistrome.shinyapps.io / timer / . The results are as follows Figure 6 As shown in D, the correlation coefficient between GDF15 expression and M2 macrophage infiltration was 0.254;
[0079] 4) Survival analysis: We sorted out the esophageal cancer survival data in the TCGA database, and then used the cutpoint function in the survminer package of the R language to select the best survival cutoff point and draw a survival curve. The results are shown in the figure below. Figure 6 As shown in C, the survival rate of patients in the high GDF15 expression group was significantly lower than that in the low GDF15 expression group;
[0080] 5) GSEA functional enrichment analysis: We divided the esophageal cancer samples in the TCGA database into high GDF15 expression group and low GDF15 expression group according to the difference between the mRNA expression of GDF15 and its average value. We used the limma package in R language to screen the differential genes between the high and low expression groups of GDF15 (the absolute value of the differential expression fold was greater than or equal to 1, P < 0.05), and then used GSEA software to perform functional enrichment analysis on the differential genes. The enrichment results are shown in Figure 2. Figure 6 As shown in K, the differentially expressed genes in the high GDF15 expression group were positively enriched in triglyceride metabolism and fatty acid oxidation metabolic pathways;
[0081] 6) Metascape gene function enrichment analysis: We performed transcriptome sequencing on esophageal squamous cell carcinoma cell EC109 co-cultured with M2-TAMs and cultured alone, screened differentially expressed genes between the non-co-culture group and the co-culture group (differential expression greater than or equal to 1, Р<0.05), and then entered the differentially expressed genes into the metascape online page https: / / metascape.org / gp / index.html# / main / step1, selected all parameters by default, and performed gene function enrichment analysis. The analysis results are shown in the figure. Figure 7 As shown in A, differentially highly expressed genes are enriched in JAK / STAT and other pathways.
[0082] 9. Detection of fatty acid β-oxidation rate and CPT1 enzyme activity
[0083] 1) Thaw the reagents in the cell mitochondria extraction kit at room temperature, and place them on ice after thawing; digest and collect the adherent cells in two 10cm culture dishes in a 15mL centrifuge tube according to the normal steps; use 1mL of 1×PBS pre-cooled in a 4℃ refrigerator to gently resuspend the cell pellet in a 1.5mL small centrifuge tube, centrifuge at 800rpm for 5 minutes, and discard the supernatant; add 1mL of mitochondrial isolation reagent to the cell pellet, gently suspend the cells, and put them in an ice bath in ice water for 15 minutes; transfer the ice-bathed cells to a 2mL glass homogenizer and homogenize 40 times; centrifuge the homogenized cell slurry at 600×g at 4℃ for 5 minutes; carefully transfer the supernatant to another new 1.5mL centrifuge tube and centrifuge at 11000×g at 4℃ for 10 minutes; carefully aspirate and discard the supernatant, and the precipitate is the isolated mitochondria; use 200μL of mitochondrial storage solution to resuspend the mitochondria for subsequent experiments.
[0084] 2) The esophageal squamous cell carcinoma cell lines EC109 and KYSE150 were treated in the following ways: control group, M2-CM group, M2-CM+GDF15 neutralizing antibody group, GDF15 recombinant protein treatment group, STAT3 pathway inhibitor stattic treatment group, GDF15 recombinant protein treatment group + STAT3 pathway inhibitor stattic treatment group. The mitochondrial samples to be tested were prepared according to the above treatment groups and placed in an ice tank for standby use; the dual-wavelength UV spectrophotometer was turned on and preheated, and the wavelength was set to 4 20nm and 470nm, read 6 times at intervals of 1 minute, and set to zero; take out the reagents in the detection kit from the -20℃ refrigerator to thaw, and pay attention to avoid light exposure to Reagent C and Reagent D; take 750μL Reagent A into a new cuvette, then add 100μL Reagent B, 50μL Reagent C, 50μL Reagent D, invert and mix, and let stand for 3 minutes; add 50μL Reagent E, invert and mix, and then put it into the spectrophotometer for detection; [(OD 420 -OD 470 )0 minutes - (OD 420 -OD 470 )5 minutes] This value is the background reading; take a new cuvette and repeat step 4), then add 500 μg of clarified mitochondrial protein and immediately put it into the spectrophotometer for detection. The sample reading is [(OD 420 -OD 470 )0 minutes - (OD 420 -OD 470 )5 minutes]; calculate the oxidation rate: [(sample reading - background reading) × 1mL × sample dilution factor] ÷ [0.5mg × 105 × 5min] = micromoles ferrocyanide reduced / minute / mg.
[0085] The results are as follows Figure 4 C, Figure 6 M, Figure 6 N, Figure 7 As shown in D, Figure 4 C shows that after treating esophageal squamous cell carcinoma cells with the conditioned medium of M2-TAMs for 48 hours, an increase in the β-oxidation rate of fatty acids in esophageal squamous cell carcinoma cells was detected; Figure 6 It can be seen that the fatty acid β-oxidation rate of the esophageal squamous cell carcinoma cell line in the M2-CM treatment group was significantly increased compared with the control group, while the addition of GDF15 neutralizing antibody inhibited the enhancing effect of M2-CM on the fatty acid β-oxidation rate of the esophageal squamous cell carcinoma cell line; Figure 6 N shows that after GDF15 recombinant protein was treated with esophageal squamous cell carcinoma cells for 48 hours, a significant increase in fatty acid β-oxidation was detected in esophageal squamous cell carcinoma cells; Figure 7D shows that compared with the control group, the fatty acid β-oxidation rate of the esophageal squamous cell carcinoma cell line in the GDF15 protein treatment group was significantly increased, while after the addition of the STAT3 pathway inhibitor stattic, the fatty acid β-oxidation rate of the esophageal squamous cell carcinoma cell line showed a significant downward trend.
[0086] 3) The esophageal squamous cell carcinoma cell lines EC109 and KYSE150 were treated in the following ways: control group, M2-CM group, M2-CM+GDF15 neutralizing antibody group, GDF15 recombinant protein treatment group, STAT3 pathway inhibitor stattic treatment group, GDF15 recombinant protein treatment group + STAT3 pathway inhibitor stattic treatment group. Mitochondrial samples were prepared in advance according to the above treatment groups and the mitochondrial protein concentration was measured; the spectrophotometer was preheated for 35 minutes in advance, the wavelength was adjusted to 412nm, and distilled water was used for zeroing; 2mL of anhydrous ethanol was added to reagent 5, mixed and then 4 Dissolve 4 mL of reagent IV, mix well, incubate at 37°C for 5 minutes, then divide the reagent and store the unused reagent at -20°C; dissolve reagent VI in 2 mL of single distilled water, mix well, incubate at 37°C for 5 minutes, divide the reagent and store the unused reagent in a -20°C refrigerator; add 40 μL of the sample to be tested, 880 μL of reagent V and 40 μL of reagent VI to a 1 mL glass cuvette, mix upside down, put it into a spectrophotometer, and record the absorbance A1 at 20 seconds and the absorbance A2 at 2 minutes and 20 seconds at a wavelength of 420 nm; calculate the CPT1 activity, the calculation formula is CPT1 (nmol / min / mg) = 880 × (A2-A1) ÷ protein concentration.
[0087] The results are as follows Figure 4 D. Figure 6 O. Figure 7 F, by Figure 4 D shows that after the conditioned medium of M2-TAMs acted on esophageal squamous cell carcinoma cells for 48 hours, the CPT1 enzyme activity in the esophageal squamous cell carcinoma cell line was detected to be increased; Figure 6 O shows that after GDF15 recombinant protein treated esophageal squamous cell carcinoma cells for 48 hours, the CPT1 enzyme activity of esophageal squamous cell carcinoma cells was significantly increased; Figure 7 F shows that compared with the control group, the CPT1 enzyme activity of the esophageal squamous cell carcinoma cell line in the GDF15 protein treatment group was significantly increased, while the CPT1 enzyme activity of the esophageal squamous cell carcinoma cell line showed a significant downward trend after the addition of the STAT3 pathway inhibitor stattic.
[0088] 10. ATP production detection
[0089] Take out the required reagents from the kit and thaw them at room temperature; treat the esophageal squamous cell carcinoma cell lines EC109 and KYSE150 in the following ways: control group, M2-CM group, M2-CM+GDF15 neutralizing antibody group, GDF15 recombinant protein treatment group, STAT3 pathway inhibitor stattic treatment group, GDF15 recombinant protein treatment group + STAT3 pathway inhibitor stattic treatment group. After 48 hours of stimulation, wash the cells with pre-cooled 1×PBS; add 200μL lysis buffer to each well, lyse the cells for 10 minutes, transfer to a 1.5mL centrifuge tube after lysis, centrifuge at 4℃, 12000×g for 5 minutes, and take the supernatant for subsequent determination; dilute the ATP standard solution with ATP detection lysis buffer to an appropriate multiple concentration gradient; according to the requirement of 100μL ATP detection working solution for each sample / standard, take out a certain amount of ATP detection agent in a 1.5mL centrifuge tube and dilute it 10 times with ATP detection diluent. The diluted ATP test was temporarily stored on ice; a new clean 1.5 mL centrifuge tube was taken, 100 μL of ATP detection agent was added, and it was placed at room temperature for 3 minutes to consume the background ATP; 30 μL of mitochondrial sample was added to the 1.5 mL centrifuge tube, and it was quickly mixed with a pipette, and the luminescence intensity value was immediately measured using a chemiluminometer; after all the standards and samples were tested, a standard curve was drawn; the concentration of ATP in the sample was calculated according to the standard curve conversion formula.
[0090] The results are as follows Figure 4 E. Figure 6 P. Figure 7 E, by Figure 4 E shows that after the conditioned medium of M2-TAMs acted on esophageal squamous cell carcinoma cells for 48 hours, the increase in ATP production in tumor cells was detected; Figure 6 P shows that after GDF15 recombinant protein treated esophageal squamous cell carcinoma cells for 48 hours, the amount of ATP generated by esophageal squamous cell carcinoma cells was significantly increased; Figure 7 E shows that compared with the control group, the ATP production of the esophageal squamous cell carcinoma cell line in the GDF15 protein treatment group was significantly increased, while the ATP production of the esophageal squamous cell carcinoma cell line showed a significant downward trend after the addition of the STAT3 pathway inhibitor stattic.
[0091] 11. Polymerase chain reaction experiment
[0092] 1) Cell treatment
[0093] According to experimental needs, the esophageal squamous cell carcinoma cell lines EC109 and KYSE150 were treated as follows: control group, CDDP treatment group, CDDP+M2-CM treatment group, GDF15 recombinant protein treatment group, si-NC group, si-STAT3 group, ov-NC group, ov-STAT3 group, and stattic treatment group.
[0094] 2) Prepare RNA samples of each experimental group using the Trizol method;
[0095] 3) Real-time fluorescence quantitative PCR
[0096] After the RNA samples and reagents were processed according to the kit instructions, the qPCR reaction system and qPCR reaction program in the instructions (denaturation and annealing / extension were set for 40 cycles in total) were used. The relative expression of the gene was measured with GAPDH as the internal reference. -△△CT The principle was calculated and whether it was specific amplification was determined based on the melting curve; the list of PCR primers is shown in Table 6.
[0097] Table 6 PCR primer list
[0098]
[0099] Results Figure 4 B. Figure 6 L. Figure 8 B. Figure 8 C. Figure 8 F; by Figure 4 B shows that qRT-PCR detection shows that under cisplatin treatment, M2-TAMs conditioned medium can promote the expression of fatty acid oxidation metabolism-related genes CPT1A, CPT1B, CPT1C, and PGC1α in esophageal squamous cell carcinoma cell lines; Figure 6 L shows that the expression of fatty acid oxidation metabolism-related genes CPT1A, CPT1B, and CPT1C in esophageal squamous cell carcinoma cell lines increased significantly after treatment with recombinant GDF15 protein; Figure 8 B shows that after knocking down STAT3 in esophageal squamous cell carcinoma cell lines, the mRNA expression of CPT1B showed a significant downward trend, while the mRNA expression of CPT1A and CPT1C showed an upward trend; Figure 8 C shows that after overexpression of STAT3 in esophageal squamous cell carcinoma cell lines, the mRNA expression of CPT1B showed a significant increasing trend, while the mRNA expression of CPT1A and CPT1C showed a decreasing trend; Figure 8 F shows that after treatment with STAT3 phosphorylation inhibitor stattic in esophageal squamous cell carcinoma cell lines, the mRNA expressions of CPT1A, CPT1B, and CPT1C showed a significant downward trend, and the mRNA expression of CPT1B decreased the most.
[0100] 12. Dual luciferase reporter gene assay
[0101] The JASPAR database was used to predict the possible binding sites of the CPT1B promoter region and STAT3. Primers were designed based on the 2000 bp sequence upstream of the CPT1B transcription start site, and the CPT1B-specific promoter fragment was amplified from genomic DNA using PCR. This fragment was inserted into the luciferase reporter gene vector PGL4-basic to form PGL4-WT (such as Figure 2 )、PGL4-MUT(such as Figure 3 ); cells in the logarithmic growth phase were seeded in 6-well plates at a confluence of 50%, and the conditions for subsequent transfection were achieved after overnight culture; the required luciferase reporter gene plasmid, target gene plasmid or small interfering RNA were transfected. For DNA transfection, the total DNA amount in the 6-well plate was 2.5 μg according to the instructions of the Lip8000 transfection reagent. The STAT3 overexpression plasmid (such as Figure 1 1:1:0.02 ratio for transfection; for small interfering RNA (as shown in Table 3), the amount of small interfering RNA per well was 100 pmol, and the concentration of CPT1B luciferase reporter gene plasmid: sea cucumber luciferase reporter gene plasmid was 1:0.02 for transfection; the medium was changed 6 hours after transfection, and the culture was continued for 48 hours; the culture medium was discarded, washed twice with 2 mL 1×PBS, and the reagents in the dual luciferase reporter gene detection kit were taken out and restored to room temperature; the reporter gene lysate was fully mixed, 300 μL was added to each well, and lysed at room temperature for 15 minutes; the cell lysate was collected and centrifuged at 12000×g for 5 minutes, and the supernatant was used for Detection; Use an appropriate amount of detection buffer to dilute the sea cucumber luciferase detection substrate (100×) into 1× sea cucumber luciferase detection working solution; Take 100μL of sample supernatant and add it to a new 1.5mL EP tube, and take an equal volume of reporter gene lysate as a blank control;) Add 100μL of firefly luciferase detection reagent and mix with a pipette, and put it into a chemiluminescence instrument to detect the luminescence intensity 1 (RLU1); After completing the firefly luciferase detection, take out the EP tube and continue to add 100μL of sea cucumber luciferase detection working solution, mix with a pipette and continue to measure the luminescence intensity 2 (RLU2); Using sea cucumber luciferin as an internal reference, calculate the ratio of RLU1 / RLU2, and compare the activation degree of the target gene promoter between different samples based on the obtained ratio.
[0102] The results are as follows Figure 8 G. Figure 8As shown in Figure H, knocking down STAT3 in wild-type esophageal squamous cell carcinoma cell lines EC109 and KYSE150 in the CPT1B promoter region can reduce the fluorescence intensity of the CPT1B promoter region, while knocking down STAT3 in esophageal squamous cell carcinoma cell lines with mutant CPT1B promoter region did not significantly change the fluorescence intensity of the CPT1B promoter region. Figure 8 H It can be seen that overexpression of STAT3 in the wild-type esophageal squamous cell carcinoma cell lines EC109 and KYSE150 in the CPT1B promoter region can increase the fluorescence intensity of the CPT1B promoter region, while the fluorescence intensity of the CPT1B promoter region did not change significantly after overexpression of STAT3 in the esophageal squamous cell carcinoma cell lines with mutant CPT1B promoter region.
[0103] The present invention, based on the clarification of a tumor-associated macrophage-mediated fatty acid β-oxidation promoting esophageal cancer chemotherapy resistance, targets tumor-associated macrophage-mediated esophageal cancer cisplatin resistance, and utilizes the fatty acid β-oxidation inhibitor Etomoxir in combination with cisplatin to improve the chemotherapy efficacy of esophageal cancer.
[0104] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
Claims
1. Application of a fatty acid oxidation inhibitor in the preparation of a product for improving cisplatin resistance in esophageal squamous cell carcinoma.
2. The use according to claim 1, characterized in that: The fatty acid oxidation inhibitor is etomoxir.
3. The use according to claim 1, characterized in that: The esophageal squamous cell carcinoma is an esophageal squamous cell carcinoma cell mediated by M2 macrophages.
4. The use according to claim 3, characterized in that: The esophageal squamous cell carcinoma cells are EC109 and / or KYSE150.
5. The use according to claim 3, characterized in that: The fatty acid oxidation inhibitor improves the cisplatin resistance of esophageal squamous cell carcinoma cells by inhibiting fatty acid β-oxidation and weakening the cisplatin resistance of esophageal squamous cell carcinoma cells induced by M2 macrophage-derived GDF15.
6. The use according to claim 5, characterized in that: The inhibition of fatty acid β-oxidation is through the inhibition of GDF15 secretion by M2 tumor-associated macrophages.
7. A drug for improving cisplatin resistance in esophageal squamous cell carcinoma cells, characterized in that: Such drugs include the fatty acid oxidation inhibitor etomoxir.
8. A drug for treating esophageal squamous cell carcinoma, characterized in that: The drugs include fatty acid oxidation inhibitors and cisplatin.
9. The drug for treating esophageal squamous cell carcinoma according to claim 8, characterized in that: The medicine also includes commonly used pharmaceutical carriers and pharmaceutical excipients.
Citation Information
Cited By
Application of SOX12 inhibitor in medicine for reducing tolerance of cis-platinum to esophageal cancer cells
CN119868563A
